HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management

Nature Reviews Clinical Oncology, Год журнала: 2022, Номер 19(5), С. 306 - 327

Опубликована: Фев. 1, 2022

Язык: Английский

---

Epidemiology and incidence of HPV‐related cancers of the head and neck

Journal of Surgical Oncology, Год журнала: 2021, Номер 124(6), С. 920 - 922

Опубликована: Сен. 23, 2021

Globally, 4.5% of cancers are due to the human papillomavirus (HPV). In United States, 80 million people infected with HPV, and incidence HPV oropharyngeal cancer has surpassed cervical cancer. The highest burden is seen in middle-aged increasingly older White men. vaccination promises change epidemiology this disease, but rates remain too low today reduce disease transmission.

Язык: Английский

---

Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer

Clinical Cancer Research, Год журнала: 2021, Номер 28(4), С. 719 - 727

Опубликована: Ноя. 29, 2021

Abstract Purpose: HPV-associated head and neck squamous cell carcinoma (HPV+HNSCC) is the most common malignancy in United States continues to increase incidence. Current diagnostic approaches for HPV+HNSCC rely on tissue biopsy followed by histomorphologic assessment detection of HPV indirectly p16 IHC. Such are invasive have variable sensitivity. Experimental Design: We conducted a prospective observational study 140 subjects (70 cases 70 controls) test hypothesis that noninvasive approach would improved accuracy, lower cost, shorter interval compared with standard approaches. Blood was collected, processed circulating tumor DNA (ctHPVDNA), analyzed custom ddPCR assays genotypes 16, 18, 33, 35, 45. Diagnostic performance, were calculated clinical workup using ctHPVDNA combined cross-sectional imaging physical examination findings. Results: Sensitivity specificity detecting 98.4% 98.6%, respectively. composite imaging/physical 95.1% accuracy this significantly higher than care (Youden index 0.937 vs. 0.707, P = 0.0006). Costs 36% 38% less median 26 days less. Conclusions: A demonstrated reduced time diagnosis could be viable alternative future.

Язык: Английский

---

Association of Pretreatment Circulating Tumor Tissue–Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer

JAMA Otolaryngology–Head & Neck Surgery, Год журнала: 2022, Номер 148(12), С. 1120 - 1120

Опубликована: Окт. 27, 2022

Circulating tumor tissue-modified viral (TTMV) human papillomavirus (HPV) DNA is a dynamic, clinically relevant biomarker for HPV-positive oropharyngeal squamous cell carcinoma. Reasons its wide pretreatment interpatient variability are not well understood.To characterize clinicopathologic factors associated with TTMV HPV DNA.This cross-sectional study included patients evaluated carcinoma at Dana-Farber Cancer Institute in Boston, Massachusetts, between December 2019 and January 2022 who were undergoing curative-intent treatment.Clinicopathologic characteristics including demographic variables, nodal staging, genotype, imaging findings.Pretreatment circulating from 5 genotypes (16, 18, 31, 33, 35) assessed using commercially available digital droplet polymerase chain reaction-based assay, considered as either detectable/undetectable or continuous score (fragments/mL).Among 110 patients, 96 men (87%) 104 White (95%), mean (SD) age of 62.2 (9.4) years. was detected 98 (89%), median (IQR) 315 (47-2686) fragments/mL (range, 0-60 061 fragments/mL). Most detectable genotype 16 (n = 86 [88%]), while 12 (12%) harbored other genotypes. detection most strongly clinical N stage. Although few had stage N0 disease, only 4 these 11 (36%) compared 94 99 (95%) N1 to N3 disease (proportion difference, 59%; 95% CI, 30%-87%). Among undetectable DNA, more than half (7 [58%]) disease. The prevalence increased progressively higher stage, diameter largest lymph node, maximum standardized uptake value on positron emission tomography/computed tomography. In multivariable analysis, each score. 27 surgically treated without lymphovascular invasion (12 [100%] vs 9 15 [60%]).In this study, statistically significantly OPSCC diagnosis. levels predominantly suggesting assay sensitivity diagnostic purposes may be lower among cervical lymphadenopathy. Mechanisms underlying association, the use surveillance baseline values, warrant further investigation.

Язык: Английский

---

Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study

Oral Oncology, Год журнала: 2025, Номер 161, С. 107179 - 107179

Опубликована: Янв. 18, 2025

Язык: Английский

---

An Assessment of Young Adults’ Awareness and Knowledge Related to the Human Papillomavirus (HPV), Oropharyngeal Cancer, and the HPV Vaccine

Cancers, Год журнала: 2025, Номер 17(3), С. 344 - 344

Опубликована: Янв. 21, 2025

Background/Objectives: The human papillomavirus (HPV) is a prevalent sexually transmitted infection that known cause of morbidities such as genital warts and cancers the cervix, anus, oropharynx. Non-cervical HPV-related have been developing problem in North America, increasing incidence by up to 225% some instances over span two decades. Methods: This study investigated levels awareness knowledge HPV, oropharyngeal cancer (OPC), HPV vaccine using self-administered web-based survey designed specifically for this research. University students (n = 1005) aged 18–30 completed 42-item questionnaire included demographic information, questions, series “true/false/I don’t know” questions. Results: data gathered revealed participants had relatively high awareness. However, many respondents significant gaps their OPC, vaccine. Collectively, indicate value vaccination may place younger individuals at risk infections. Conclusions: Although level concerning was observed, suggest further efforts are necessary educate young adults. While all factors cannot be reduced, present guide future directed toward better education on related health concerns associated risks.

Язык: Английский

---

Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium

Journal of Clinical Oncology, Год журнала: 2022, Номер 40(31), С. 3613 - 3622

Опубликована: Июнь 14, 2022

PURPOSE Seropositivity for the HPV16-E6 oncoprotein is a promising marker early detection of oropharyngeal cancer (OPC), but absolute risk OPC after positive or negative test unknown. METHODS We constructed an prediction model that integrates (1) relative odds serostatus and cigarette smoking from human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population factor data National Health Interview Survey, (3) sex-specific rates mortality. RESULTS The nine HPVC3 cohorts included 365 participants with up to 10 years between blood draw diagnosis 5,794 controls. estimated 10-year seropositive males at age 50 was 17.4% (95% CI, 12.4 28.6) 60 27.1% 19.2 45.4). Corresponding 5-year estimates were 7.3% 14.4%, respectively. For females, 3.6% 2.5 5.9) 5.5% 3.8 9.2) 1.5% 2.7%, Over 30 years, result 49.9% 13.3% females would develop OPC. By contrast, risks among seronegative people very low, ranging 0.01% 0.25% depending on age, sex, status. CONCLUSION estimate substantial proportion individuals will OPC, 17%-27% 4%-6% 50-60 in United States. This high level may warrant periodic, minimally invasive surveillance serology test, particularly high-incidence regions. However, appropriate clinical protocol remains be established.

Язык: Английский

---

HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage

Cancer Treatment Reviews, Год журнала: 2022, Номер 111, С. 102467 - 102467

Опубликована: Окт. 5, 2022

Язык: Английский

---

Circulating Tumor HPV DNA for Surveillance of HPV-Positive Oropharyngeal Squamous Cell Carcinoma

JAMA Oncology, Год журнала: 2023, Номер 9(12), С. 1716 - 1716

Опубликована: Окт. 12, 2023

Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma has an overall favorable prognosis, yet a subset of patients will experience devastating disease recurrence. Current surveillance standards for detection recurrent are imperfect. There is growing interest in improving through the use plasma-based assays able to detect circulating tumor HPV DNA.Although most DNA remain research domain, tissue-modified viral assay became commercially available United States early 2020 and been increasingly used clinical setting. With rapidly increasing incidence HPV-positive concomitant expansion biomarker capabilities this disease, it critical reexamine current posttreatment practices determine whether emerging technologies may be improve outcomes survivor population. However, caution advised; not known biomarker-based truly beneficial, as true with any intervention, capacity cause harm.Using Margaret Pepe's classic 5 phases development cancer framework, article reviews state knowledge, highlights existing knowledge gaps, suggests that should prioritized understand association between patient outcomes. Specific attention paid assay, given its use. This review serve road map future guide clinicians considering adoption practice. Enrollment into trials incorporating prioritized.

Язык: Английский

---

Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus–Associated Cancers

Journal of Molecular Diagnostics, Год журнала: 2023, Номер 26(3), С. 179 - 190

Опубликована: Дек. 15, 2023

Human papillomavirus (HPV)-associated cancers, including oropharyngeal squamous cell carcinoma (HPV + OPSCC), cervical cancer, and of the anus SCCA), release circulating tumor HPV DNA (ctHPVDNA) into blood. The diagnostic performance ctHPVDNA detection depends on approaches used individual assay metrics. A comparison these has not been systematically performed to inform expected performance, which in turn affects clinical interpretation. meta-analysis was using Ovid MEDLINE, Embase, Web Science Core Collection databases assess accuracy across cancer anatomic sites, platforms, blood components. population included patients with OPSCC, HPV-associated SCCA pretreatment samples analyzed by quantitative PCR (qPCR), digital droplet (ddPCR), or next-generation sequencing (NGS). Thirty-six studies involving 2986 met inclusion criteria. sensitivity, specificity, quality each study were assessed pooled for analysis. sensitivity greatest NGS, followed ddPCR then qPCR when pooling all studies, whereas specificity similar (sensitivity: > qPCR, P < 0.001; NGS ddPCR, = 0.014). from OPSCC more easily detected compared SCCA, overall (P 0.044). In conclusion, platform, site component must be considered interpreting results. Plasma NGS-based testing may most sensitive approach overall. papillomaviruses (HPVs) are a family oncoviruses that cause benign malignant lesions genital mucosa, upper respiratory tract, skin. More than 200 distinct types have identified, at least 14 them classified as high risk, capable tumorigenesis, specific sites.1Saraiya M. Unger E.R. Thompson T.D. Lynch C.F. Hernandez B.Y. Lyu C.W. Steinau Watson Wilkinson E.J. Hopenhayn C. Copeland G. Cozen W. Peters E.S. Huang Y. Saber M.S. Altekruse S. Goodman M.T. Typing Cancers WorkgroupU.S. assessment cancers: implications current 9-valent vaccines.J Natl Cancer Inst. 2015; 107: djv086Crossref PubMed Scopus (529) Google Scholar, 2Bzhalava D. Guan P. Franceschi Dillner J. Clifford systematic review prevalence mucosal cutaneous human types.Virology. 2013; 445: 224-231Crossref (226) 3Bouvard V. Baan R. Straif K. Grosse Secretan B. El Ghissassi F. Benbrahim-Tallaa L. Guha N. Freeman Galichet Cogliano WHO International Agency Research Monograph Working GroupA carcinogens—part B: biological agents.Lancet Oncol. 2009; 10: 321-322Abstract Full Text PDF Scholar accounts 5% cancers worldwide causes almost cases well significant proportion vaginal, vulvar, penile, anal, rectal, cancers.4de Martel Plummer Vignat Worldwide burden attributable site, country type.Int J Cancer. 2017; 141: 664-670Crossref (1283) 5Goodman Saraiya Tucker T. genotype oropharynx survival United States America.Eur 51: 2759-2767Abstract (72) 6Alemany Saunier Alvarado-Cabrero I. Quirós Salmeron Shin H.-R. Pirog E.C. Guimerà Hernandez-Suarez Felix A. Clavero O. Lloveras Kasamatsu E. Laco Tinoco Geraets D.T. Mandys Poljak Jach Verge Clavel Ndiaye Klaustermeier Cubilla Castellsagué X. Bravo I.G. Pawlita Quint W.G. Muñoz Bosch F.X. de Sanjosé VVAP Study GroupHuman type distribution anal carcinomas worldwide.Int 136: 98-107Crossref (280) 7Forman Lacey C.J. Soerjomataram Lortet-Tieulent Bruni Ferlay Bray Global related diseases.Vaccine. 2012; 30: F12-F23Crossref (1214) 8Baricevic He Chakrabarty Oliver A.W. Bailey Summers Hampson Gilbert D.C. Renehan A.G. High-sensitivity papilloma virus genotyping reveals near universal positivity carcinoma: different vaccine prevention prognosis.Eur 776-785Abstract (68) Routine screening strategies CC), pelvic examinations Papanicolaou smears, enable early contributed substantial reduction incidence early-stage cancer.9Peirson Fitzpatrick-Lewis Ciliska Warren Screening cancer: meta-analysis.Syst Rev. 2: 35Crossref (276) Scholar,10Whitlock E.P. Vesco K.K. Eder Lin J.S. Senger C.A. Burda B.U. Liquid-based cytology screen U.S. Preventive Services Task Force.Ann Intern Med. 2011; 155 (W214-5): 687-697Crossref (148) Unlike effective OPSCC) SCCA) lacking, steadily increased past few decades.11Deshmukh A.A. Suk Shiels Sonawane Nyitray Liu Gaisa M.M. Palefsky J.M. Sigel Recent trends mortality States, 2001-2015.J 2020; 112: 829-838Crossref (166) Kingdom, men surpassed rates women continues rise, despite vaccination efforts.12Lechner Jones O.S. Breeze C.E. Gilson Gender-neutral UK, rising male rates, lack awareness.Lancet Infect Dis. 2019; 19: 131-132Abstract (34) 13Centers Disease Control Prevention: Associated Papillomavirus, States—2015–2019. USCS Data Brief, no. 31. Centers Prevention, US Department Health Services, Atlanta, GA:2022https://www.cdc.gov/cancer/uscs/about/data-briefs/no31-hpv-assoc-cancers-UnitedStates-2015-2019.htm#Date accessed: December 29, 2023Google 14Tota J.E. Best A.F. Zumsteg Z.S. Gillison M.L. Rosenberg P.S. Chaturvedi A.K. Evolution epidemic States: moderation increasing younger individuals shift older individuals.J Clin 37: 1538-1546Crossref (107) 15Zhang Fakhry D'Souza Projected association US, 2020-2045.JAMA 2021; 7e212907Crossref (49) 16Chaturvedi Engels E.A. Pfeiffer R.M. Xiao Kim Jiang Sibug-Saber Wentzensen Jordan R.C. Anderson W.F. States.J 29: 4294-4301Crossref (2815) Existing diagnose monitor invasive, costly, variable accuracy, indicating need improve standard care. Circulating (ctDNA) is released secreted cells other body fluids.17Siravegna Marsoni Siena Bardelli Integrating liquid biopsies management cancer.Nat Rev 14: 531-548Crossref (1279) 18Cescon D.W. Bratman S.V. Chan S.M. Siu L.L. biopsy oncology.Nat 1: 276-290Crossref (267) 19Wan J.C.M. Massie Garcia-Corbacho Mouliere Brenton J.D. Caldas Pacey Baird Rosenfeld Liquid come age: towards implementation tumour DNA.Nat 17: 223-238Crossref (1600) 20Crowley Di Nicolantonio Loupakis biopsy: monitoring cancer-genetics blood.Nat 472-484Crossref (1348) 21Pascual Attard Bidard F.-C. Curigliano De Mattos-Arruda Diehn Italiano Lindberg Merker Montagut Normanno Pantel Pentheroudakis Popat Reis-Filho Tie Seoane Tarazona Yoshino Turner N.C. ESMO recommendations use assays report Precision Medicine Group.Ann 2022; 33: 750-768Abstract (156) 22Thierry A.R. Messaoudi Gahan P.B. Anker Stroun Origins, structures, functions oncology.Cancer Metastasis 2016; 35: 347-376Crossref (550) Results detecting ctDNA shown broad applicability, molecular profiling, adaptive treatment during therapy, minimal residual disease, recurrence detection.23Dawson S.-J. Tsui D.W.Y. Murtaza Biggs H. Rueda O.M. Chin S.-F. Dunning M.J. Gale Forshew Mahler-Araujo Rajan Humphray Becq Halsall Wallis Bentley Analysis metastatic breast cancer.N Engl 368: 1199-1209Crossref (1751) 24Chen Zhao Shi Yang Wang L.T. Kang Nie Perioperative dynamic changes lung (DYNAMIC).Clin Res. 25: 7058-7067Crossref (129) 25Bettegowda Sausen Leary R.J. Kinde Agrawal et al.Detection early- late-stage malignancies.Sci Transl 2014; 6: 224ra224Crossref (3381) 26Stejskal Goodarzi Srovnal Hajdúch van't Veer L.J. Magbanua M.J.M. nucleic acids: biology, mechanisms, relevance.Mol 2023; 22: 15Crossref (28) 27Bernard D.U. San Lucas F.A. Castillo Allenson Mulu F.C. Stephens B.M. Semaan Guerrero P.A. Kamyabi Hurd M.W. Koay Taniguchi C.M. Herman Javle Wolff Katz Varadhachary Maitra Alvarez H.A. acids associated outcomes pancreatic cancer.Gastroenterology. 156: 108-118.e104Abstract (251) 28Li R.-Y. Liang Z.-Y. real-time disease evolution response.Chin Med (Engl). 133: 2476-2485Crossref (13) 29Magbanua Swigart L.B. Wu H.-T. Hirst G.L. Yau Wolf D.M. Tin Salari Shchegrova Pawar Delson A.L. DeMichele M.C. Chien A.J. Tripathy Asare C.-H.J. Billings Aleshin Sethi Louie Zimmermann Esserman neoadjuvant-treated reflects response survival.Ann 32: 229-239Abstract (167) 30Schwarzenbach Alix-Panabières Müller Letang Vendrell J.-P. Rebillard Cell-free plasma marker prostate cancer.Clin 15: 1032-1038Crossref (211) 31Tie Tomasetti Li Springer Silliman Tacey Wong H.-L. Christie Kosmider Skinner Steel Tran Desai Haydon Hayes Price T.J. Strausberg R.L. Diaz Jr., L.A. Papadopoulos Kinzler K.W. Vogelstein Gibbs analysis detects predicts stage II colon cancer.Sci 8346ra392Crossref (963) 32Tie Cohen Simons Lee Ananda McKendrick Cho J.H. Faragher I.T. Ptak Schaeffer Dobbyn analyses markers risk benefit adjuvant therapy III cancer.JAMA 5: 1710-1717Crossref (345) 33Reinert Henriksen T.V. Christensen Sharma al.Analysis cell-free ultradeep stages I colorectal 1124-1131Crossref (470) (ctHPVDNA), advantages over somatic due smaller size viral genome its cells, making an optimal target application biopsies.34Faden D.L. diagnosis head neck cancer.Cancer Cytopathol. 130: 12-15Crossref (3) Numerous detectable serum time diagnosis. It can biomarker detect earlier care imaging.35Cao Banh Kwok Krakow Khong Bavan Bala Pinsky B.A. Colevas Pourmand Koong A.C. Kong C.S. Le Q.-T. Quantitation patients.Int Radiat Oncol Biol Phys. 82: e351-e358Abstract (97) 36Ahn J.Y.K. Zhang Z. Khan Bishop J.A. Westra Koch W.M. Califano Saliva polymerase chain reaction-based surveillance papillomavirus-related Otolaryngol Head Neck Surg. 140: 846-854Crossref 37Chera B.S. Kumar Beaty B.T. Marron Jefferys Green Goldman Amdur Sheets Dagan D.N. Weiss Grilley-Olson Zanation Hackman Blumberg Patel Weissler Tan X.M. Parker Mendenhall Gupta G.P. Rapid clearance profile 16 chemoradiotherapy correlates control 4682-4690Crossref (178) 38Chera Shen Thorp Yarbrough cancer.J 38: 1050-1058Crossref 39Hanna G.J. Lau Mahmood U. Supplee J.G. Mogili Haddad R.I. Janne Paweletz C.P. Salivary informs locoregional status advanced cancer.Oral 95: 120-126Crossref (31) 40Damerla R.R. N.Y. You Soni Shah Reyngold Katabi McBride Tsai Riaz Powell S.N. Babady N.E. Viale Higginson D.S. Detection papillomavirus-associated biopsy.JCO Precis 3PO.18.00276PubMed 41Naegele Efthymiou Das Sadow P.M. Richmon Iafrate Faden sinonasal nasopharyngeal cancers.JAMA 149: 179-181Crossref (5) 42Jeannot Becette Campitelli Calméjane M.-A. Lappartient Ruff Saada Holmes Bellet Sastre-Garau diagnosed invasive carcinoma.J Pathol 201-209Crossref (122) 43Jeannot Latouche Bonneau Beaufort Ruigrok-Ritstier Bataillon Larbi Chérif Dupain Lecerf Popovic la Rochefordière Lecuru Fourchotte Jordanova von der Leyen Tran-Perennou Legrier M.-E. Dureau Raizonville Bello Roufai Tourneau Bièche Rouzier Berns E.M.J.J. Kamal Scholl relapse 27: 5869-5877Crossref (35) 44Bernard-Tessier Jeannot Guenat Debernardi Michel Proudhon Vincent-Salomon Pierga J.-Y. Buecher Meurisse François Jary Vendrely Samalin Hajbi Baba-Hamed Borg Clinical validity ancillary epitopes-HPV02 trial.Clin 2109-2115Crossref (59) 45Naegele Hirayama Double trouble: synchronous metachronous primaries confound monitoring.Head Neck. 45: E25-E30Crossref (1) ctHPVDNA-based diagnostics improved reduced cost, shorter existing tissue-based diagnostics.46Siravegna O'Boyle Varmeh Queenan Stein Thierauf Faquin W.C. Perry S.K. Bard A.Z. Deschler D.G. Emerick K.S. Varvares M.A. Park J.C. Clark J.R. Andreu Arasa V.C. Sakai Lennerz Corcoran R.B. Wirth provides accurate rapid 28: 719-727Crossref (36) past, conventional (qPCR) common method ctDNA, but newer (and costly) techniques, droplet-digital (ddPCR) (NGS), emerged.47Postel Roosen Laurent-Puig Taly Wang-Renault Droplet-based next generation DNA: perspective.Expert Mol Diagn. 2018; 18: 7-17Crossref literature influences We tested hypothesis superior cancers. medical librarian (D.G.) following guidelines Preferred Reporting Items Systematic Reviews Meta-Analyses.48Moher Liberati Tetzlaff Altman PRISMA GroupPreferred reporting items reviews meta-analyses: statement.Ann 151 (W64): 264-269Crossref (19877) search published MEDLINE (Wolters-Kluwer, 1946–February 2022), Embase (Elsevier, 1947–February Collections (Clarivate, 1900–February 2022) designed conducted reference February 18 23, 2022. (Registration required access databases.) Search customized database. Each combination controlled vocabulary key word terms relating (head neck, cervical, penile) testing. constructed exclude non-human studies. No filters language, design, date publication, origin search, produced 251 articles (Figure 1). All references exported EndNote X7.8 Philadelphia, PA). Duplicates removed first automated process manually librarian; this left 153 articles, Covidence (Melbourne, VIC, Australia) screening, selection, data extraction. Nine subsequent found through searching thus yielding total 162 screening. Studies examined any eligible inclusion. Extracted comprised following: subsite; status; method; number assay; true-positive, false-positive, false-negative, true-negative findings; source (plasma serum); probe gene (if used); amplicon hybrid capture used). Only written English included. Titles abstracts screened independently two authors (S.N. D.A.R.-T.) full-text review. same Any disagreements settled discussion consensus between authors. duplicate comparing authors, timeframe collection, outcomes. After full text 36 remained synthesis. R 4.1.2 (R Foundation Statistical Computing, Vienna, Austria; https://cran.r-project.org) conduct statistical packages "meta" "metafor" meta-analysis. missing one values [true positive, false negative (TP, FN) true negative, positive (TN, FP)] excluded. Using random effects model, 95% confidence intervals (CIs), computed TP FN, CI TN FP. Subgroups defined differently means calculated respectively. Subsequently, separate meta-regressions test characteristic sensitivities specificities. Interstudy variability between-study variance Cochran's Q statistic. percentage variation explained heterogeneity opposed sampling error I2 two-sided 0.05 significant. Potential publication bias evaluated Quality Assessment Diagnostic Accuracy Studies-2 tool (https://www.bristol.ac.uk/population-health-sciences/projects/quadas/quadas-2). judged low answers signaling questions four domains yes no, If information sufficient, unclear used. Most flow timing index 2). Notably, standard, three patient bias. Regarding 33 test, five selection. containing (Table 135Cao Scholar,40Damerla Scholar,42Jeannot 46Siravegna Scholar,49Cabel Bernard-Tessier Héquet Féron J.-G. Brun J.-F. Benoît Rodrigues Scher

Язык: Английский

---